Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

3
ESMO-MCBS v1.1
Scorecard version: 1

Indication details

Tumour Type
Refractory NTRK fusion–positive cancers
Tumour stage
Locally advanced or metastatic
Control Arm
Single arm trials
Treatment Setting
Treatment of patients whose solid tumours have a neurotrophic tyrosine receptor kinase gene fusion

Primary Outcome(s)

Primary Outcome(s)
ORR,DOR
Evaluated Outcome
ORR,DOR
Form(s)
Form 3

Outcome Data

PFS Control
11.2 months
ORR
57%
DoR
10.4 months

Final Score (after adjustments)

Preliminary non-curative score
3
Final non-curative Score
3
Issue date
23.07.2020

DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; FFS, failure-free survival; HR, hazard ratio; iDFS, invasive disease-free survival; ITT, intention to treat; MFS, metastasis-free survival; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate; SD, stable disease; SSA, somatostatin analogue; SSTR, somatostatin receptor; TKI, tyrosine kinase inhibitor, TTP, time to progression

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings